<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410382</url>
  </required_header>
  <id_info>
    <org_study_id>1408439554</org_study_id>
    <nct_id>NCT02410382</nct_id>
  </id_info>
  <brief_title>Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer</brief_title>
  <official_title>A Phase II Randomized Study of Short-Term Dexamethasone Versus Placebo for Fatigue in Patients Receiving Radiation Alone or Radiation and Chemotherapy for the Treatment of Head and Neck and Non-Small Cell Lung Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at how dexamethasone and placebo influence radiation fatigue, quality of
      life and number of treatment days missed during radiation therapy or radiation therapy and
      chemotherapy for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will randomly receive either dexamethasone or placebo and begin the study medication
      during the midpoint of their radiation treatment. Study medication will be taken for 14
      straight days then stopped. Fatigue and quality of life will be measured weekly with short
      patient completed surveys. The number of breaks taken during radiation treatment will also be
      tracked. For safety, blood sugar levels will be checked with finger stick blood draws because
      dexamethasone is known to cause these levels to increase. Study participation will be
      approximately 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    IRB suspension, did not resume
  </why_stopped>
  <start_date type="Actual">August 27, 2014</start_date>
  <completion_date type="Actual">February 16, 2018</completion_date>
  <primary_completion_date type="Actual">February 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue Measured by FACIT-F Version 4 Fatigue Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare the effects of dexamethasone and placebo on radiation fatigue using validated measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by FACIT-F Version 4 Well-Being Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the effect of dexamethasone on QoL and radiation therapy treatment interruption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>oral dexamethasone 4 mg bid for 14 days</description>
    <arm_group_label>Arm 2 Dexamethasone</arm_group_label>
    <other_name>corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral placebo</description>
    <arm_group_label>Arm 1 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmation of head &amp; neck cancer (stage I-IV) or non-small cell lung cancer (stage
             II &amp; III)

          -  Undergoing treatment with either radiation alone or in combination with chemotherapy

          -  Normal cognition and willingness to complete fatigue and quality of life forms,
             patient observation form, and pill diary

        Exclusion Criteria:

          -  Hypersensitivity to dexamethasone or corticosteroids or Equal sugar substitute

          -  Corticosteroid within the past 30 days prior to study enrollment for greater than one
             week duration

          -  Planned Stereotactic Body Radiation Therapy (SBRT)

          -  Active psychosis

          -  Current pregnancy

          -  Active peptic ulcer disease or evidence of gastrointestinal bleed

          -  Current active tuberculosis or systemic fungal infection

          -  Previous diagnosis of diabetes mellitus

          -  Acute febrile illness

          -  Known human immunodeficiency virus or acquired immunodeficiency syndrome

          -  Major surgery within two weeks of study enrollment of which the patient has not
             recovered

          -  Psychostimulant use in the past 30 days prior to registration

          -  History of phenylketonuria (PKU)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Yi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>April 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2019</results_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02410382/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study was terminated and data coordinator is no longer in the institution. Sincere efforts were made to gather and report the data, however, no data are available since the study records cannot be located.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 Placebo</title>
          <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
Placebo: oral placebo</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 Dexamethesone</title>
          <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
Dexamethasone: oral dexamethasone 4 mg bid for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study was terminated by IRB - attempts made to obtain info were unsuccessful.</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study was terminated by IRB - attempts made to obtain info were unsuccessful.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 Placebo</title>
          <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
Placebo: oral placebo</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 Dexamethesone</title>
          <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
Dexamethasone: oral dexamethasone 4 mg bid for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fatigue Measured by FACIT-F Version 4 Fatigue Score</title>
        <description>To compare the effects of dexamethasone and placebo on radiation fatigue using validated measures</description>
        <time_frame>12 weeks</time_frame>
        <population>Data were collected but could not be analyzed. Study terminated by IRB and any data that were gathered, are lost. No data are available for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Placebo</title>
            <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
Placebo: oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Dexamethesone</title>
            <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
Dexamethasone: oral dexamethasone 4 mg bid for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Measured by FACIT-F Version 4 Fatigue Score</title>
          <description>To compare the effects of dexamethasone and placebo on radiation fatigue using validated measures</description>
          <population>Data were collected but could not be analyzed. Study terminated by IRB and any data that were gathered, are lost. No data are available for this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by FACIT-F Version 4 Well-Being Score</title>
        <description>To determine the effect of dexamethasone on QoL and radiation therapy treatment interruption</description>
        <time_frame>12 weeks</time_frame>
        <population>Data were collected but could not be analyzed. Study terminated by IRB and any data that were gathered, are lost. No data are available for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 Placebo</title>
            <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
Placebo: oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Dexamethesone</title>
            <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
Dexamethasone: oral dexamethasone 4 mg bid for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by FACIT-F Version 4 Well-Being Score</title>
          <description>To determine the effect of dexamethasone on QoL and radiation therapy treatment interruption</description>
          <population>Data were collected but could not be analyzed. Study terminated by IRB and any data that were gathered, are lost. No data are available for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data unavailable; study terminated. Good faith attempts made to locate any data have been unsuccessful.</time_frame>
      <desc>Data unavailable; study terminated. Good faith attempts made to locate any data have been unsuccessful.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 Placebo</title>
          <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
Placebo: oral placebo</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 Dexamethesone</title>
          <description>Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
Dexamethasone: oral dexamethasone 4 mg bid for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sun K. Yi</name_or_title>
      <organization>University of Arizona</organization>
      <phone>(520) 694-7236</phone>
      <email>sunkyi@email.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

